Positive Development in NICE Cabozantinib Appraisal Appeal

A NICE appeal panel has upheld three key appeal points on cabozantinib for advanced neuroendocrine tumours, sending the appraisal back to committee for further consideration. It is not yet a recommendation for routine NHS use — but it keeps important evidence on survival benefit under review.